Todd Berard Sells 1,577 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 1,577 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now directly owns 104,961 shares in the company, valued at approximately $2,624,025. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Todd Berard also recently made the following trade(s):

• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Stock Down 0.2 %

BLFS stock opened at $25.00 on Friday. The business’s 50-day moving average is $26.59 and its two-hundred day moving average is $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter last year, the company earned ($0.21) earnings per share. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BLFS shares. Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. HC Wainwright increased their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Finally, KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.86.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. D.A. Davidson & CO. raised its stake in BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after purchasing an additional 519 shares during the period. Stifel Financial Corp raised its stake in BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 670 shares during the period. 1620 Investment Advisors Inc. raised its stake in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the period. Smartleaf Asset Management LLC raised its stake in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new stake in BioLife Solutions during the 4th quarter valued at approximately $26,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.